Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial).
Bousmah MA, Nishimwe ML, Tovar-Sanchez T, Lantche Wandji M, Mpoudi-Etame M, Maradan G, Omgba Bassega P, Varloteaux M, Montoyo A, Kouanfack C, Delaporte E, Boyer S; New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-Income Countries (NAMSAL) ANRS 12313 Study Group. Bousmah MA, et al. Among authors: varloteaux m. Pharmacoeconomics. 2021 Mar;39(3):331-343. doi: 10.1007/s40273-020-00987-3. Epub 2020 Dec 23. Pharmacoeconomics. 2021. PMID: 33355914 Free PMC article.
Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon.
Calmy A, Tovar Sanchez T, Kouanfack C, Mpoudi-Etame M, Leroy S, Perrineau S, Lantche Wandji M, Tetsa Tata D, Omgba Bassega P, Abong Bwenda T, Varloteaux M, Tongo M, Mpoudi-Ngolé E, Montoyo A, Mercier N, LeMoing V, Peeters M, Reynes J, Delaporte E; New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-Income Countries (NAMSAL) ANRS 12313 Study Group. Calmy A, et al. Among authors: varloteaux m. Lancet HIV. 2020 Oct;7(10):e677-e687. doi: 10.1016/S2352-3018(20)30238-1. Lancet HIV. 2020. PMID: 33010241 Clinical Trial.
Rapid Increase of Community SARS-CoV-2 Seroprevalence during Second Wave of COVID-19, Yaoundé, Cameroon.
Ndongo FA, Guichet E, Mimbé ED, Ndié J, Pelloquin R, Varloteaux M, Esemu L, Mpoudi-Etame M, Lamare N, Edoul G, Wouambo RK, Djomsi DM, Tongo M, Tabala FN, Dongmo RK, Diallo MSK, Bouillin J, Thaurignac G, Ayouba A, Peeters M, Delaporte E, Bissek AZ, Mpoudi-Ngolé E. Ndongo FA, et al. Among authors: varloteaux m. Emerg Infect Dis. 2022 Jun;28(6):1233-1236. doi: 10.3201/eid2806.212580. Epub 2022 Apr 26. Emerg Infect Dis. 2022. PMID: 35470795 Free PMC article.
Large Diffusion of Severe Acute Respiratory Syndrome Coronavirus 2 After the Successive Epidemiological Waves, Including Omicron, in Guinea and Cameroon: Implications for Vaccine Strategies.
Diallo MSK, Amougou-Atsama M, Ayouba A, Kpamou C, Mimbe Taze ED, Thaurignac G, Diallo H, Lamare NB, Bouillin J, Soumah AK, Noah SA, Guichet E, Keita AK, Varloteaux M, Peeters M, Bissek AZ, Toure A, Delaporte E, Kouanfack C. Diallo MSK, et al. Among authors: varloteaux m. Open Forum Infect Dis. 2023 Apr 20;10(5):ofad216. doi: 10.1093/ofid/ofad216. eCollection 2023 May. Open Forum Infect Dis. 2023. PMID: 37152188 Free PMC article.
Improvements in Patient-Reported Outcomes Following Initiation of Dolutegravir-Based or Low-Dose Efavirenz-Based First-Line Antiretroviral Therapy: A Four-Year Longitudinal Analysis in Cameroon (NAMSAL ANRS 12313 Trial).
Bousmah MA, Protopopescu C, Mpoudi-Etame M, Omgba Bassega P, Maradan G, Olinga J, Varloteaux M, Tovar-Sanchez T, Delaporte É, Kouanfack C, Boyer S; NAMSAL ANRS 12313 Study Group. Bousmah MA, et al. Among authors: varloteaux m. J Acquir Immune Defic Syndr. 2023 Nov 1;94(3):262-272. doi: 10.1097/QAI.0000000000003273. J Acquir Immune Defic Syndr. 2023. PMID: 37851566 Clinical Trial.
Durability of the Efficacy and Safety of Dolutegravir-Based and Low-Dose Efavirenz-Based Regimens for the Initial Treatment of Human Immunodeficiency Virus Type 1 Infection in Cameroon: Week 192 Data of the NAMSAL-ANRS-12313 Study.
Mpoudi-Etame M, Tovar Sanchez T, Bousmah MA, Omgba Bassega P, Olinga J, Mimbe E, Foalem M, Chiep C, Edimo S, Varloteaux M, Pelloquin R, Lamare N, Boyer S, Peeters M, Reynes J, Calmy A, Hill A, Delaporte E, Kouanfack C; New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-income countries (NAMSAL-ANRS-12313) study group. Mpoudi-Etame M, et al. Among authors: varloteaux m. Open Forum Infect Dis. 2023 Nov 20;10(12):ofad582. doi: 10.1093/ofid/ofad582. eCollection 2023 Dec. Open Forum Infect Dis. 2023. PMID: 38156046 Free PMC article.
Research priorities for accelerating the achievement of three 95 HIV goals in Cameroon: a consensus statement from the Cameroon HIV Research Forum (CAM-HERO).
Dzudie A, Tchounga B, Ajeh R, Kouanfack C, Ebasone PV, Djikeussi T, Nyoto LB, Fokam J, Ateudjieu J, Tchendjou P, Semengue ENJ, Kamgang FY, Anoubessi J, Varloteaux M, Youngui B, Tabala FN, Atanga B, Simo L, Zemsi A, Shu EN, Ndayisaba G, Nyenti A, Ntabe AC, Bwemba TA, Sobngwi E, Billong SC, Ditekemena J, Bissek ACZ, Njock LR. Dzudie A, et al. Among authors: varloteaux m. Pan Afr Med J. 2021 Oct 29;40:124. doi: 10.11604/pamj.2021.40.124.31068. eCollection 2021. Pan Afr Med J. 2021. PMID: 34909092 Free PMC article.
Outcomes of the first meeting of the CAMEROON HIV RESEARCH FORUM (CAM-HERO).
Tchounga B, Ajeh R, Djikeussi T, Ebasone PV, Tchendjou P, Anoubissi J, Semengue ENJ, Nkouanfack C, Kamgang FY, Varloteaux M, Tchakounte BY, Tabala FN, Atanga B, Simo L, Ateudjieu J, Zemsi A, Nasah LJ, Ngeke NG, Ndiforkwah N, Bouseko MT, Sandjong FT, Shu EN, Bakari M, Tiojio Y, Ndayisaba G, Annereke N, Ntabe AC, Bwemba TA, Billong SC, Bisseck ACZ, Ditekemena J, Dzudie A. Tchounga B, et al. Among authors: varloteaux m. Pan Afr Med J. 2021 Nov 17;40:166. doi: 10.11604/pamj.2021.40.166.31058. eCollection 2021. Pan Afr Med J. 2021. PMID: 34970408 Free PMC article.
19 results